Clinical Research DNA Genomics Life Science 
Drug Discovery World
OCTOBER 16, 2023
Maina Bhaman, Partner at Sofinnova Partners, says: “The UK is an attractive space for drug discovery companies and a prime environment for investment due to its talent, infrastructure, and genomics research. CellProthera also appointed the Newcastle Centre for Life’s GMP cell therapy centre to produce the ATMP.”
XTalks
NOVEMBER 7, 2022
Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. These tumor-derived entities are used to derive genomic and proteomic data. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
MAY 23, 2024
Eterovic brings much knowledge and experience to the table, having led the development of a new Oncology Diagnostic program at Eurofins Viracor that integrates the latest genomic profiling techniques. Eterovic highlights that the financial and logistical barriers to comprehensive genomic profiling are high but not impossible to overcome.
Roots Analysis
AUGUST 28, 2022
As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players.
XTalks
FEBRUARY 4, 2021
The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Partnerships and Establishing Research Cohorts. Genomic biomarker discovery helps drive the development of innovative new personalized therapies.
Drug Discovery World
APRIL 29, 2024
Bill Dawson, Chair, Medicines Manufacturing Industry Partnership (MMIP): Dawson is Head of Biologics and Devices Manufacturing at GSK and has over 25 years’ experience in the vaccines, biopharma, pharmaceutical and clinical research (CRO) industries. He is lead inventor on 28 US patents linked to genome sequencing.
Drug Discovery World
AUGUST 10, 2022
If the gene does not integrate into the genome, the cell will not become a CAR T cell. Furthermore, even if the transgene enters the cell in the correct numbers, the location where the gene integrates into the genome is somewhat random. The gene could also bury itself in a silenced region of the genome, leaving the gene dormant.
Expert insights. Personalized for you.
75 
Let's personalize your content